Main Management LLC cut its position in SPDR S&P Biotech ETF (NYSEARCA:XBI) by 5.6% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 152,783 shares of the exchange traded fund’s stock after selling 9,069 shares during the quarter. SPDR S&P Biotech ETF accounts for 2.1% of Main Management LLC’s portfolio, making the stock its 18th largest position. Main Management LLC owned 0.27% of SPDR S&P Biotech ETF worth $14,647,000 at the end of the most recent quarter.

Several other hedge funds have also recently made changes to their positions in the company. Pinnacle Wealth Management Advisory Group LLC purchased a new position in shares of SPDR S&P Biotech ETF in the third quarter valued at $499,000. Hartline Investment Corp boosted its stake in SPDR S&P Biotech ETF by 26.1% during the 3rd quarter. Hartline Investment Corp now owns 38,227 shares of the exchange traded fund’s stock valued at $3,665,000 after acquiring an additional 7,901 shares during the last quarter. PNC Financial Services Group Inc. boosted its stake in SPDR S&P Biotech ETF by 33.8% during the 3rd quarter. PNC Financial Services Group Inc. now owns 28,417 shares of the exchange traded fund’s stock valued at $2,724,000 after acquiring an additional 7,186 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in SPDR S&P Biotech ETF by 7.0% during the 3rd quarter. Bank of New York Mellon Corp now owns 21,854 shares of the exchange traded fund’s stock valued at $2,095,000 after acquiring an additional 1,435 shares during the last quarter. Finally, Claraphi Advisory Network LLC boosted its stake in SPDR S&P Biotech ETF by 46.4% during the 3rd quarter. Claraphi Advisory Network LLC now owns 3,456 shares of the exchange traded fund’s stock valued at $331,000 after acquiring an additional 1,096 shares during the last quarter.

NYSEARCA XBI opened at $76.45 on Wednesday. SPDR S&P Biotech ETF has a 12 month low of $73.97 and a 12 month high of $101.55.

TRADEMARK VIOLATION WARNING: This piece was published by Daily Political and is the property of of Daily Political. If you are reading this piece on another website, it was stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.dailypolitical.com/2018/11/21/main-management-llc-has-14-65-million-stake-in-spdr-sp-biotech-etf-xbi.html.

About SPDR S&P Biotech ETF

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.

See Also: Inflation

Institutional Ownership by Quarter for SPDR S&P Biotech ETF (NYSEARCA:XBI)

Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.